Napo Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Napo Pharmaceuticals's estimated annual revenue is currently $2M per year.
- Napo Pharmaceuticals's estimated revenue per employee is $100,500
- Napo Pharmaceuticals's total funding is $12.1M.
Employee Data
- Napo Pharmaceuticals has 20 Employees.
- Napo Pharmaceuticals grew their employee count by 25% last year.
Napo Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | National Business Director | Reveal Email/Phone |
3 | Specialty Territory Business Manager | Reveal Email/Phone |
4 | Specialty Territory Manager | Reveal Email/Phone |
5 | Senior Product Marketing Manager | Reveal Email/Phone |
6 | Oncology Account Manager | Reveal Email/Phone |
7 | Oncology Account Manager | Reveal Email/Phone |
8 | Specialty Territory Manager | Reveal Email/Phone |
9 | Specialty Pharmaceuticals Sales Manager & Field Reimbursement Manager | Reveal Email/Phone |
10 | Medical Affairs | Reveal Email/Phone |
Napo Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $102.7M | 511 | 25% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $38.6M | 192 | 3% | N/A | N/A |
#4 | $35M | 127 | 2% | $62.5M | N/A |
#5 | $36.6M | 182 | 18% | N/A | N/A |
#6 | $131.9M | 656 | -3% | N/A | N/A |
#7 | $133.5M | 664 | N/A | N/A | N/A |
#8 | $72.8M | 362 | -4% | N/A | N/A |
#9 | $551.9M | 1716 | -2% | N/A | N/A |
#10 | $11.7M | 58 | 12% | N/A | N/A |
What Is Napo Pharmaceuticals?
Napo Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company based in South San Francisco, California. Founded in November 2001, Napo is developing a late-stage drug candidate, crofelemer, for gastrointestinal indications including chronic diarrhea in persons living with HIV/AIDS. Additionally, Napo has entered into a licensing agreement for the worldwide development and commercialization of crofelemer for Irritable Bowel Syndrome. Napo is also working with private/public partners to jointly develop crofelemer for pediatric indications in the developing world while maintaining commercial rights in the developed world.
keywords:N/A
$12.1M
Total Funding
20
Number of Employees
$2M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Napo Pharmaceuticals News
Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human...
Chaturvedi served as Chair of the company's SAB and Acting CSO of Jaguar and Napo Pharmaceuticals (Napo), Jaguar's wholly owned subsidiary. "We...
Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing...
SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc., announced today that it has obtained $2 million in secured convertible debt financing from New York-based Kingdon Capital Management, LLC. Proceeds from the financing will primarily be used by Napo for the commercialization of Mytesi™. ...
Salix licensed crofelemer in 2008 from San Francisco, California drug developer Napo Pharmaceuticals, an agreement that paid Napo $4.5 million and called for Salix to be responsible for development of the compound. Crofelemer had been granted fast-track status by the U.S. Food and Drug Administr ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 20 | -5% | N/A |
#2 | $1.5M | 20 | 67% | $331.5M |
#3 | $2M | 20 | N/A | N/A |
#4 | $2M | 20 | N/A | N/A |
#5 | $1.4M | 20 | -9% | $5.9M |